 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...2324252627282930313233...4748» |
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: AK105 Combined With Anlotinib in Patients With Cervical Cancer (clinicaltrials.gov) - Nov 29, 2021
P2, N=36, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal: In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy. (Pubmed Central) - Nov 29, 2021
Anrotinib combined with radiotherapy can synergistically inhibit tumor cell growth.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A. (Pubmed Central) - Nov 29, 2021
Animal studies showed that A549/anlotinib cell-derived exosomal miR-136-5p agomir promoted A549 cell anlotinib resistance in vivo. Collectively, these findings indicated that anlotinib-resistant NSCLC cell-derived exosomal miR-136-5p confers anlotinib resistance in NSCLC cells by targeting PPP2R2A, indicating miR-136-5p may act as a potential biomarker for anlotinib response in NSCLC.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient. (Pubmed Central) - Nov 29, 2021
The patient's overall survival time was more than 5 months and developed oral ulcer and acute cerebral infarction during his oral administration of anlotinib. This patient showed a favorable clinic outcome for treatment of leptomeningeal spread recurrent GBM with anlotinib and didn't show serious side effects.
- AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm, autologous tumor infiltrating lymphocytes / Origincell
AN EXPLORATORY PILOT TRIAL EVALUATING TUMOR INFILTRATING LYMPHOCYTES THERAPY ON RELAPSED OSTEOSARCOMA ([VIRTUAL]) - Nov 26, 2021 - Abstract #CTOS2021CTOS_145;
Ligon et all presented data which supported that osteosarcoma PMs are more highly infiltrated by immune cells compared with primary tumors. Notably, tumors that demonstrate increased CD8 T cell infiltration and decreased PD-L1 expression were associated with improved PFS, suggesting that even in these relatively cold tumors the degree of immune response may influence the patient’s outcome.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
PRELIMINARY RESULTS OF PHASE II SINGLE-ARM STUDY ON PREOPERATIVE INTENSITY-MODULATED RADIOTHERAPY WITH CONCURRENT ANLOTINIB FOR PATIENTS WITH NON-METASTATIC EXTREMITY AND TRUNK SOFT TISSUE SARCOMA ([VIRTUAL]) - Nov 26, 2021 - Abstract #CTOS2021CTOS_56;
For patients with non-metastatic extremity or trunk primary sarcoma, the combination of Anlotinib and pre-operative radiotherapy is safe and well-tolerated, and achieve favorable clinical and pathological response. The earlier response with addition of Anlotinib make more patients with unresectable or borderline resectable tumor completely resected by limb-conserving wide resection.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: EASOAIPPGL: A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial (clinicaltrials.gov) - Nov 23, 2021
P2, N=20, Recruiting, Sponsor: Nanjing First Hospital, Nanjing Medical University
- || Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
New P2 trial, Combination therapy: CC-ANNIE: Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. (clinicaltrials.gov) - Nov 22, 2021
P2, N=20, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || Gilotrif (afatinib) / Boehringer Ingelheim, Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Review, Journal: Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature. (Pubmed Central) - Nov 21, 2021
This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P2 data, Journal: Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial. (Pubmed Central) - Nov 21, 2021
This is the first study to evaluate the efficacy and safety of anlotinib in Chinese patients with recurrent or metastatic CC. Anlotinib produced durable clinical responses with manageable safety in these patients.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ALTER-UC-001: Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Nov 18, 2021
P2, N=30, Not yet recruiting, Sponsor: Fudan University
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer. (Pubmed Central) - Nov 17, 2021
Both TNM stage and brain metastasis were independent risk factors for OS and PFS. DEB-BACE concomitant with anlotinib has promising efficacy and tolerable toxicity in patients with advanced NSCLC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Biomarker, Retrospective data, Journal: Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study. (Pubmed Central) - Nov 16, 2021
Anlotinib was effective in treating locally advanced or advanced lung cancer. High pretreatment PNI scores and the presence of hand-foot syndrome after treatment were independent prognostic markers for favorable OS and PFS.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P3 trial, Metastases: A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 15, 2021
P3, N=256, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2858 / Sino Biopharm
New P2 trial, Metastases: A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma (clinicaltrials.gov) - Nov 15, 2021
P2, N=113, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
The Efficacy and Safety of TQ-B2450 alone/with Anlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial (Room C [VIRTUAL]) - Nov 13, 2021 - Abstract #ESMOIO2021ESMO_IO_395;
P1
Conclusion A significantly and clinically meaningful improvement in PFS with TQ-B2450 plus anlotinib versus TQ-B2450 alone in all patients, supporting TQ-B2450 plus anlotinib as a promising treatment for advanced/metastatic NSCLC pts with prior systemic therapy. Clinical trial identification NCT03910127.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, Monotherapy, Real-world evidence: Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study. (Pubmed Central) - Nov 12, 2021
Patients who experienced a hypertension adverse reaction induced by anlotinib therapy might confer superior PFS. The conclusion should be validated in prospective clinical trials subsequently.
- | Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Retrospective data, Journal: Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis. (Pubmed Central) - Nov 12, 2021
Ramucirumab+CT and PD-1 inhibitors were superior to CT for previously treated cases of advanced esophageal/EGJ cancer. Ramucirumab+CT seemed to be the most effective treatment in patients with esophageal/EGJ AC, while use of PD-1 inhibitors, especially camrelizumab, was likely to be the optimal treatment in patients with esophageal SCC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal: Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. (Pubmed Central) - Nov 10, 2021
TACE combined with anlotinib is safe and may improve outcomes for unresectable HCC patients comparing with TACE alone. Randomized controlled trials are warranted to further evaluate treatment effects of anlotinib in HCC.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, Real-world evidence: Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer. (Pubmed Central) - Nov 9, 2021
Anlotinib is beneficial to refractory SCLC as third- or further-line treatment, especially in patients without liver metastasis and with better physical status. Related adverse effects are tolerable and manageable.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P2 trial: ALTER-H006: TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (clinicaltrials.gov) - Nov 7, 2021
P2, N=37, Not yet recruiting, Sponsor: Xianhai Mao
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. (Pubmed Central) - Nov 6, 2021
In those without previous thoracic RT patients, anlotinib might have DCR and PFS benefits compared with placebo. The safety was similar between anlotinib and placebo groups.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Combination therapy, Metastases: Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (clinicaltrials.gov) - Nov 4, 2021
P2, N=32, Recruiting, Sponsor: Peking Union Medical College Hospital
The safety was similar between anlotinib and placebo groups. Not yet recruiting --> Recruiting
- | Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment status: To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. (clinicaltrials.gov) - Nov 2, 2021
P=N/A, N=80, Recruiting, Sponsor: Shanghai Chest Hospital
Not yet recruiting --> Recruiting Enrolling by invitation --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Increased Esophageal Perforation After Combination of Anti-PD-1 Immunotherapy With Radiotherapy for Esophageal Carcinoma (McCormick Place West, Room W178 a/b) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_638;
We observed a higher incidence of perforation when anti-PD-1 immunotherapy and esophageal RT were administered in patients with esophageal carcinoma, especially anti-PD-1 immunotherapy administered after RT. Owing to the limitations of this study, the results warrant further confirmation.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib in Combination With Whole Brain Radiotherapy for Advanced Non–Small-Cell Lung Cancer With Brain Metastases Progressive or Developed After at Least One Lines of Prior Treatment (Digital XP) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_133;
This retrospective analysis demonstrated that the combination of anlotinib and WBRT is associated with better iPFS than WBRT in NSCLC patients with intracranial metastasis failed to standard systematic treatment. Randomized, prospective studies are needed to further validate these findings.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
PD-L1 on the endothelium of micrangium inside tumor: a novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 (TQ-B2450) ? (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_317;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Avastin (bevacizumab) / Roche
Immunotherapy-based strategies displayed a promising efficacy in non-small cell lung cancer (NSCLC) patients with non-EGFR oncogenic genetic alterations (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_278;
P=N/A
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
Novel anti-PD-L1 antibody TQB2450 (T) in combination with anlotinib (A) in patients with advanced soft tissue sarcoma (STS), the results from the expanded sample size and updated data (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_271;
Funding China International Medical Foundation (No. Z-2014-06-15331).
- AL-034 / J&J, Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase Ib study of the TLR7 agonist TQ-A3334 monotherapy or combined with Anlotinib or PD-L1 inhibitor in treatment of advanced metastatic non-small cell lung cancer (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_270;
P1/2
Funding Chia Tai Tianqing Pharmaceutic Group Co. Ltd.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Stereotactic body radiotherapy (SBRT) plus anlotinib with or without toripalimab in driver mutation-negative non-small cell lung cancer (NSCLC) patients with untreated brain oligometastatic metastases: a prospective, single-center, phase Ib Study (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_242;
P1
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Combining Sintilimab with Anlotinib as Second-Line or Later Therapy in Patients with Extensive-Disease Small Cell Lung Cancer: A Prospective, Single-Arm, Phase 2 Trial. (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_200;
P2
Legal entity responsible for the study The authors. Funding Has not received any funding.
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
WATCH: @bvantine1, of @WUSTLmed, discusses next steps with catequentinib in soft tissue sarcoma. #scmsm https://t.co/zDh96PTfhA (Twitter) - Oct 29, 2021
- | AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Increased Esophageal Perforation After Combination of Anti-PD-1 Immunotherapy With Radiotherapy for Esophageal Carcinoma. (Pubmed Central) - Oct 29, 2021
Owing to the limitations of this study, the results warrant further confirmation. However, careful consideration should be given to the possibility of an increased risk of perforation in patients treated with anti-PD-1 immunotherapy after esophageal RT, and careful monitoring for perforation is recommended.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Combination therapy: Anlotinib in Combination With Whole Brain Radiotherapy for Advanced Non-Small-Cell Lung Cancer With Brain Metastases Progressive or Developed After at Least One Lines of Prior Treatment. (Pubmed Central) - Oct 29, 2021
This retrospective analysis demonstrated that the combination of anlotinib and WBRT is associated with better iPFS than WBRT in NSCLC patients with intracranial metastasis failed to standard systematic treatment. Randomized, prospective studies are needed to further validate these findings.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P2 data, Journal: Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). (Pubmed Central) - Oct 29, 2021
Anlotinib showed promising efficacy and safety as a first- or second-line treatment with a continuous TKIs treatment strategy in aHCC. The plasma CXCL1 might be a predictor for the efficacy of anlotinib.
- || AiRuiKa (camrelizumab) / Jiangsu Hengrui Medicine, Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. (Pubmed Central) - Oct 29, 2021
Anlotinib plus camrelizumab had shown promising efficacy and manageable toxicity as a second-line or later-line treatment for NSCLCs, especially in the 12 mg cohorts. Large-scale phase III clinical trials are needed to further explore the rational combination models and biomarkers.
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P3 data, Journal, Monotherapy: Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703). (Pubmed Central) - Oct 27, 2021
However, overall survival was similar between the two groups. In a word, in third-line or above treatment of Chinese patients with refractory metastatic colorectal cancer, anlotinib provided clinical benefit by significantly prolonged progression-free survival.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal: The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer. (Pubmed Central) - Oct 27, 2021
Additionally, functional targeting BDNF-TrkB pathway with neutralizing antibodies against BDNF and TrkB increased the sensitivity of GC cells towards anlotinib in human patient-derived organoid (PDO) model. Taken together, these results characterize a critical role of the epithelial-stroma interaction mediated by the lactate/BDNF/TrkB signaling in GC anlotinib resistance, and provide a novel option to overcome drug resistance.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Observational data, Journal: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. (Pubmed Central) - Oct 27, 2021
The preliminary data showed that the combination of anlotinib and anti-PD-1 antibodies demonstrated promising durable antitumor efficacy with acceptable toxicity in patients with various advance tumors, and promoted favorable changes in serum IL-2, IL-4, IL-10, TNF-α, IFN-γ levels and circulating immune cell subsets in clinical responders. It is worth to further validate the efficacy in a randomized prospective trial.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal: Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study. (Pubmed Central) - Oct 22, 2021
It is worth to further validate the efficacy in a randomized prospective trial. Anlotinib is a potential treatment option for unresectable local recurrence or metastatic WDLS/DDLS.
- || Ivesa (firmonertinib) / Allist, ArriVent, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date, Metastases: FOCUS-A: Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (clinicaltrials.gov) - Oct 21, 2021
P2, N=40, Recruiting, Sponsor: Shanghai Chest Hospital
Anlotinib is a potential treatment option for unresectable local recurrence or metastatic WDLS/DDLS. Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Oct 2021
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Oct 21, 2021
P2, N=35, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. (clinicaltrials.gov) - Oct 20, 2021
P=N/A, N=80, Enrolling by invitation, Sponsor: Shanghai Chest Hospital
Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Oct 2021 Not yet recruiting --> Enrolling by invitation
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: QLMM-01: Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma (clinicaltrials.gov) - Oct 20, 2021
P2, N=29, Not yet recruiting, Sponsor: Qilu Hospital of Shandong University
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical: Catequentinib significantly prolonged PFS in patients with synovial sarcoma who experienced disease progression following anthracycline-containing therapies. @bvantine1 @SitemanCenter #scmsm https://t.co/P2Kl7IrffG (Twitter) - Oct 17, 2021
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, HEOR: Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China. (Pubmed Central) - Oct 13, 2021
P2
Not yet recruiting --> Enrolling by invitation Anlotinib is likely to be a cost-effective option compared with placebo for patients with relapsed SCLC who experience failure of at least two lines of chemotherapy in China.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Oct 12, 2021
P3, N=270, Recruiting, Sponsor: Advenchen Laboratories, LLC
Anlotinib is likely to be a cost-effective option compared with placebo for patients with relapsed SCLC who experience failure of at least two lines of chemotherapy in China. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov) - Oct 12, 2021
P2, N=46, Recruiting, Sponsor: Guangdong Provincial People's Hospital
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Not yet recruiting --> Recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Oct 11, 2021
P2, N=40, Recruiting, Sponsor: Zhejiang Cancer Hospital